Andrew J. Dannenberg YOU? Author Swipe

Last 10y

Data from Association of a Healthy Lifestyle Index with Risk of Breast Cancer among Women with Normal Body Mass Index in the UK Biobank Open

Andrew J. Dannenberg · 2025

Background:A high healthy lifestyle index (HLI), a composite score based on good diet quality, low alcohol consumption, no smoking, moderate to high physical activity, and waist circumference 2). Whether the HLI is associated with br…

ApoM-bound S1P acts via endothelial S1PR1 to suppress choroidal neovascularization and vascular leakage Open

B. Jung, Hitomi Yagi, Andrew Kuo, Tim F. Dorweiler, Masanori Aikawa , et al. · 2025

Table S2 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

This table provides details on where each cathepsin enzyme was obtained.

Figure S2 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Shows binding assay performance and differential MetAP2 binding of test compounds.

Figure S1 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Shows the structures of the PDC, the benzenesulfonate salt form of the physiologically active small molecule, and three test compounds, along with the numbering system utilized for NMR assignment of evexomostat.

Table S7 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Detailed results from each behavioural measurement conducted in rats to assess potential CNS toxicity of SDX-7320.

Table S1 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Displays the proton and carbon NMR assignments for evexomostat, including chemical shifts, multiplicities and coupling constants, for evexomostat under the experimental conditions shown based on the numbering system presented in Figure S1.

Table S6 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Levels of small molecule MetAP2 inhibitors SDX-7539 and TNP-470 in plasma and CSF, used to assess CNS penetration.

Table S3 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Results of competition for radioligand binding by SDX-9402 at different receptors, to assess the selectivity of the MetAP2 inhibitor against known drug targets.

Table S6 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Levels of small molecule MetAP2 inhibitors SDX-7539 and TNP-470 in plasma and CSF, used to assess CNS penetration.

Figure S5 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

This graph displays the exposure-time profile of SDX-7539 in rats after IV administration of SDX-7320 or SDX-7539.

Table S4 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Results of enzyme assays that assessed the potential inhibitory activity of the MetPA2 inhibitor against various enzymes.

Figure S6 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Variance in the expression of genes between control and SDX-7320-treated tumor samples is displayed in this graph.

Table S4 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Results of enzyme assays that assessed the potential inhibitory activity of the MetPA2 inhibitor against various enzymes.

Figure S6 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Variance in the expression of genes between control and SDX-7320-treated tumor samples is displayed in this graph.

Figure S1 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Shows the structures of the PDC, the benzenesulfonate salt form of the physiologically active small molecule, and three test compounds, along with the numbering system utilized for NMR assignment of evexomostat.

Figure S4 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

These results demonstrate the lack of MetAP1 aminopeptidase inhibition by SDX-7539 and TNP-470, and supports the findings regarding selectivity of these compounds for MetAP2.

Data from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Methionine aminopeptidase type 2 (METAP2) is a ubiquitous, evolutionarily conserved metalloprotease fundamental to protein biosynthesis which catalyzes removal of the N-terminal methionine residue from nascent polypeptides. METAP2 is an at…

Supplementary Data from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Contains methods and results from additional experiments

Table S5 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Detailed information from the x-ray crystallography of SDX-7539 bound to MetAP2 that enabled determination of the co-crystal’s 3D structure.

Figure S2 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Shows binding assay performance and differential MetAP2 binding of test compounds.

Figure S4 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

These results demonstrate the lack of MetAP1 aminopeptidase inhibition by SDX-7539 and TNP-470, and supports the findings regarding selectivity of these compounds for MetAP2.

Supplementary Data from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Contains methods and results from additional experiments

Table S3 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Results of competition for radioligand binding by SDX-9402 at different receptors, to assess the selectivity of the MetAP2 inhibitor against known drug targets.

Table S5 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Detailed information from the x-ray crystallography of SDX-7539 bound to MetAP2 that enabled determination of the co-crystal’s 3D structure.

Figure S3 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Compares the 3D crystal structures of MetAP2 with SDX-7539 bound to that of MetAP2 with TNP-470

Table S2 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

This table provides details on where each cathepsin enzyme was obtained.

Table S7 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Detailed results from each behavioural measurement conducted in rats to assess potential CNS toxicity of SDX-7320.

Figure S3 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

Compares the 3D crystal structures of MetAP2 with SDX-7539 bound to that of MetAP2 with TNP-470

Figure S5 from Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity Open

Peter Cornelius, Benjamin A. Mayes, John S. Petersen, David J. Turnquist, Pierre J. Dufour , et al. · 2024

This graph displays the exposure-time profile of SDX-7539 in rats after IV administration of SDX-7320 or SDX-7539.

Fetching topic information...